Everfront Biotech Inc.
June 24, 2026
Theater 4
Type: Company Presentation
Focus Area:
Orphan and Rare Disease
Everfront Biotech is a clinical-stage company developing innovative therapies for diseases with high unmet medical need, with an initial focus on glioblastoma and pancreatic cancer. The Company’s platform combines small-molecule therapeutics with local sustained-delivery technologies designed to improve efficacy in tumors with significant treatment barriers and biological complexity. Its lead asset, Cerebraca Wafer, is being developed for recurrent glioblastoma and is expected to enter a pivotal study, with first patient in anticipated in Q4 2026. Everfront is also pursuing pancreatic cancer as an expansion opportunity using the same local delivery platform. In parallel, the Company is advancing soft capsule candidates as systemic therapies for oncology. Phase II results for Cerebraca Wafer showed median overall survival of 15.7 months in recurrent glioblastoma and 26.2 months in biomarker-positive patients.
Company HQ City:
Taipei
Company HQ State:
Taipei
Company HQ Country:
Taiwan
Year Founded:
2010
Lead Product in Development:
Cerebraca Wafer
CEO
Pei-Wen Chou
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
3 (Cerebraca Wafer, EF-009, and HK-001)
When you expect your next catalyst update?
6-month
What is your next catalyst (value inflection) update?
Cerebraca Wafer Phase IIb/III: first patient in and first data readout in recurrent glioblastoma.
EF-009 PhaseI/IIa: first patient in and dose-escalation readout in pancreatic cancer.
HK-001 Phase I: healthy volunteer dose-escalation and safety readout.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}